Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors

Cancer Treatment Reviews

Volumn 39, Issue 8, 2013, Pages 974-984

  Polk, Anne ^a   Vaage Nilsen, Merete ^a   Vistisen, Kirsten ^a   Nielsen, Dorte L ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

5 fluorouracil; Capecitabine; Cardiotoxicity; Systematic review

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTERFERON; IRINOTECAN; LAPATINIB; METHOTREXATE; MITOMYCIN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEPTICHEMIO; VINCRISTINE;

BOLUS INJECTION; BREAST CANCER; BREAST TUMOR; CANCER PATIENT; CANCER RADIOTHERAPY; CARDIOGENIC SHOCK; CARDIOTOXICITY; CARDIOVASCULAR MORTALITY; CLINICAL FEATURE; COLORECTAL CANCER; CONTINUOUS INFUSION; DISEASE PREDISPOSITION; DYSPNEA; ELECTROCARDIOGRAM; ESOPHAGUS CANCER; GALLBLADDER CANCER; HEAD AND NECK CANCER; HEART ARREST; HEART INFARCTION; HEART PALPITATION; HUMAN; HYPOTENSION; INCIDENCE; META ANALYSIS (TOPIC); METASTASIS; MONOTHERAPY; PANCREAS CANCER; REVIEW; RISK ASSESSMENT; SINGLE DRUG DOSE; STOMACH CANCER; SYSTEMATIC REVIEW; THORAX PAIN; UNIVARIATE ANALYSIS;

5-FLUOROURACIL; CAPECITABINE; CARDIOTOXICITY; SYSTEMATIC REVIEW;

DEOXYCYTIDINE; FLUOROURACIL; HEART DISEASES; HUMANS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 84883550748     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.03.005     Document Type: Review

References (57)

1. Becker K., Erckenbrecht J.F., Haussinger D., et al. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 1999, 57:475-484.
2. Saif M.W., Shah M.M., Shah A.R. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 2009, 8:191-202.
3. Meydan N., Kundak I., Yavuzsen T., et al. Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up. Jpn J Clin Oncol 2005, 35:265-270.
4. Ceyhan C., Meydan N., Barutca S., et al. Influence of high-dose leucovorin and 5-fluorouracil chemotherapy regimen on P wave duration and dispersion. J Clin Pharm Ther 2004, 29:267-271.
5. Ceyhan C., Meydan N., Barutca S., et al. Ultrasound tissue characterization by integrated backscatter for analyzing fluorouracil induced myocardial damage. Echocardiography 2005, 22:233-238.
6. Oztop I., Gencer M., Okan T., et al. Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers. Jpn J Clin Oncol 2004, 34:262-268.
7. Van C.E., Hoff P.M., Blum J.L., et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 2002, 13:484-485.
8. Akhtar S.S., Salim K.P., Bano Z.A. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology 1993, 50:441-444.
9. Holubec L., Topolcan O., Finek J., et al. Dynamic monitoring of cardio-specific markers and markers of thyroid gland function in cancer patients - a pilot study. Anticancer Res 2007, 27:1883-1886.
10. de F.M., Malet-Martino M.C., Jaillais P., et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992, 10:1795-1801.
11. Balloni L., Porta C., Rossi S., et al. Left ventricular function in colon cancer patients receiving adjuvant fluoro-folate chemotherapy: an echocardiographic study. Oncol Rep 2000, 7:887-890.
12. Eskilsson J., Albertsson M., Mercke C. Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil. Radiother Oncol 1988, 13:41-46.
13. Jensen S.A., Hasbak P., Mortensen J., et al. Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. J Clin Oncol 2010, 28:5280-5286.
14. Jensen S.A., Sorensen J.B. 5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity. Cancer Chemother Pharmacol 2012, 69:57-64.
15. Jeremic B., Jevremovic S., Djuric L., et al. Cardiotoxicity during chemotherapy treatment with 5-fluorouracil and cisplatin. J Chemother 1990, 2:264-267.
16. Koca D., Salman T., Unek I., et al. Clinical and electrocardiography changes in patients treated with capecitabine. Chemotherapy 2011, 57(5):381-387.
17. Kosmas C., Kallistratos M.S., Kopterides P., et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008, 134:75-82.
18. Meyer C.C., Calis K.A., Burke L.B., et al. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 1997, 17:729-736.
19. Ng M., Cunningham D., Norman A.R. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer 2005, 41:1542-1546.
20. Rezkalla S., Kloner R.A., Ensley J., et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 1989, 7:509-514.
21. Salepci T., Seker M., Uyarel H., et al. 5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels. Med Oncol 2010, 27:416-420.
22. Sudhoff T., Enderle M.D., Pahlke M., et al. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol 2004, 15:661-664.
23. Wacker A., Lersch C., Scherpinski U., et al. High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients. Oncology 2003, 65:108-112.
24. Yilmaz U., Oztop I., Ciloglu A., et al. 5-fluorouracil increases the number and complexity of premature complexes in the heart: a prospective study using ambulatory ECG monitoring. Int J Clin Pract 2007, 61:795-801.
25. Gradishar W., Vokes E., Schilsky R., et al. Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience. Med Pediatr Oncol 1991, 19:8-15.
26. Jensen S.A., Sorensen J.B. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006, 58:487-493.
27. Keefe D.L., Roistacher N., Pierri M.K. Clinical cardiotoxicity of 5-fluorouracil. J Clin Pharmacol 1993, 33:1060-1070.
28. Khan M.A., Masood N., Husain N., et al. A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center. J Pak Med Assoc 2012, 62:430-434.
29. Labianca R., Beretta G., Clerici M., et al. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 1982, 68:505-510.
30. Orditura M., De V.F., Sarubbi B., et al. Analysis of recovery time indexes in 5-fluorouracil-treated cancer patients. Oncol Rep 1998, 5:645-647.
31. Pottage A., Holt S., Ludgate S., et al. Fluorouracil cardiotoxicity. Br Med J 1978, 1:547.
32. Schober C., Papageorgiou E., Harstrick A., et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 1993, 72:2242-2247.
33. Tsibiribi P., Descotes J., Lombard-Bohas C., et al. Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease. Bull Cancer 2006, 93:E27-E30.
34. Weidmann B., Jansen W., Heider A., et al. 5-Fluorouracil cardiotoxicity with left ventricular dysfunction under different dosing regimens. Am J Cardiol 1995, 75:194-195.
35. Centurion O.A. Clinical implications of the P wave duration and dispersion: relationship between atrial conduction defects and abnormally prolonged and fractionated atrial endocardial electrograms. Int J Cardiol 2009, 134:6-8.
36. Turgut O., Tandogan I., Yilmaz M.B., et al. Association of P wave duration and dispersion with the risk for atrial fibrillation: practical considerations in the setting of coronary artery disease. Int J Cardiol 2010, 144:322-324.
37. Perez M.V., Dewey F.E., Marcus R., et al. Electrocardiographic predictors of atrial fibrillation. Am Heart J 2009, 158:622-628.
38. Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N Engl J Med 1998, 339:321-328.
39. Stein B.C., Levin R.I. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J 1998, 135:914-923.
40. Balion C., Santaguida P.L., Hill S., et al. Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure. Evid Rep Technol Assess (Full Rep) 2006, 1-147.
41. Zeng X., Li L., Su Q. The prognostic value of N-terminal pro-brain natriuretic peptide in non-ST elevation acute coronary syndromes: a meta-analysis. Clin Chem Lab Med 2012, 50:731-739.
42. Yamada S., Komuro K. Integrated backscatter for the assessment of myocardial viability. Curr Opin Cardiol 2006, 21:433-437.
43. Naito J., Masuyama T., Yamamoto K., et al. Myocardial integrated ultrasonic backscatter in patients with old myocardial infarction: comparison with radionuclide evaluation. Am Heart J 1996, 132:54-60.
44. Onbasili O.A., Erdogan S., Tekten T., et al. Dipyridamole stress echocardiography and ultrasonic myocardial tissue characterization in predicting myocardial ischemia, in comparison with dipyridamole stress Tc-99m MIBI SPECT myocardial imaging. Jpn Heart J 2004, 45:937-948.
45. Milunski M.R., Mohr G.A., Perez J.E., et al. Ultrasonic tissue characterization with integrated backscatter. Acute myocardial ischemia, reperfusion, and stunned myocardium in patients. Circulation 1989, 80:491-503.
46. Yuda S., Dart J., Najos O., et al. Use of cyclic variation of integrated backscatter to assess contractile reserve and myocardial viability in chronic ischemic left ventricular dysfunction. Echocardiography 2002, 19:279-287.
47. Mosseri M., Fingert H.J., Varticovski L., et al. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 1993, 53:3028-3033.
48. Malet-Martino M., Jolimaitre P., Martino R. The prodrugs of 5-fluorouracil. Curr Med Chem Anticancer Agents 2002, 2:267-310.
49. Schuller J., Cassidy J., Dumont E., et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000, 45:291-297.
50. Reigner B., Blesch K., Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001, 40:85-104.
51. Altundag O., Celik I., Kars A. Recurrent asymptomatic bradycardia episodes after cisplatin infusion. Ann Pharmacother 2001, 35:641-642.
52. Canobbio L., Fassio T., Gasparini G., et al. Cardiac arrhythmia: possible complication from treatment with cisplatin. Tumori 1986, 72:201-204.
53. Tassinari D., Sartori S., Drudi G., et al. Cardiac arrhythmias after cisplatin infusion: three case reports and a review of the literature. Ann Oncol 1997, 8:1263-1267.
54. Ma H., Jones K.R., Guo R., et al. Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: role of endoplasmic reticulum stress. Clin Exp Pharmacol Physiol 2010, 37:460-465.
55. El-Awady el-S.E., Moustafa Y.M., Abo-Elmatty D.M., et al. Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. Eur J Pharmacol 2011, 650:335-341.
56. Bashir H., Crom D., Metzger M., et al. Cisplatin-induced hypomagnesemia and cardiac dysrhythmia. Pediatr Blood Cancer 2007, 49:867-869.
57. Wang J., He D., Zhang Q., et al. Resveratrol protects against Cisplatin-induced cardiotoxicity by alleviating oxidative damage. Cancer Biother Radiopharm 2009, 24:675-680.